No Data
No Data
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating
Solid Biosciences Announces Clinical Pipeline Updates: SGT-003 Tolerated In Duchenne Trial; SGT-212 FA Study For 2H 2025; SGT-501 IND Submission By H1 2025; $148.9M Cash Funding Through 2026
Express News | Solid Biosciences Inc - Cash and Investments Expected to Fund Key Strategic Priorities Into 2026
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
Insider Sale: CFO & Treasurer of $SLDB (SLDB) Sells 4,073 Shares
JMP Securities Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $15